Abbott, F. 22, 67, 103, 113, 115, 123
Abbott, K. 49, 55
Abi-Saab, George 61
abuse of dominant position see forward-base regulatory model
Advisory Centre on WTO law 55
Africa 12, 115
African Regional Industrial Property Organisation 67
agriculture 100
exclusivity for test data 88–9
AIDS/HIV 66–7, 86
Albin, C. 100
Allott, P. 170
amics curiae 13
Andean Community 19
Anheuser-Busch 73
animals 17–18, 20, 21, 75–6
see also Convention on Biological Diversity
Argentina 16, 55, 56
Arup, C. 7, 12, 13, 20
Asia 121
see also individual countries
Australia 37, 114, 152, 164
Australia v France 176
bilateral FTAs 18–19, 114
United States 18–19, 20–24, 148–50, 152
disputes 16
Bacchus, J. 61, 62
Banks, J. 162
Barrie, G. 168
Bartels, L. 15
Beier, F.-K. 75
Berne Convention 15, 40, 41, 50, 105, 107
compulsory licences 109, 110–11
bilateral FTAs 11–12, 18–20, 31, 35–6, 114, 116
biotechnological inventions, patenting of 75–6
conclusions 93–4
data exclusivity 22, 88–9
digital technologies 91–3
extension of IP rights and balance of interests 106–7
forward-base regulatory model and 179–80
introduction 71–2
patent system, revision of 86–8
pharmaceuticals, patent protection for 20, 22–4, 81–3
compulsory licensing 83–4
parallel import, restraining 85–6
revocation of patents, prohibiting 85
plant varieties, patenting of 76–8
trademarks 89–91
traditional knowledge and genetic resources, protection of 78–81
US see under United States
biological diversity see Convention on Biological Diversity
biotechnological inventions and patents 75–6
Blakeney, M. 79
Bonell, M. 171–2, 173
Bowett, D. 167
Braithwaite, J. 8, 17
brands 90–91, 108
Bannon, L. 90
Brazil 16, 37, 38, 55, 56, 57, 83, 115
Briggs, H. 167
Brown, R. 90
Budapest Treaty 105
Cambodia 84
Canada 22, 23, 37, 83
Canada – Terms of Patent Protection
116, 117
Carley, K. 162–3
Central America 121
Chang, H. 39
Chaudri, A. 90
Chile 179–80
China 19, 37, 112–13, 121, 135, 163–4
coercion see forward-base regulatory model
Cohen, J. 93
competitive and cooperative interpretation
bilateral FTAs 18–20
Australia-United States 18–19, 20–24
conclusions 24–5
dynamics 6–7
constitutionalism 10–12
legal pluralism 7–8
vertical and horizontal links 8–10
introduction 6
WTO dispute settlement
changing tack 16–17
negotiated interpretations 12–13
receptive adjudication 13–16
shifting forum 17–18
compulsory licences 110, 115, 116
copyrighted materials 109, 110–11
translation 109
Doha Declaration 16, 17, 82, 83, 84, 115, 116, 123
United States 20, 83–4
AUSFTA 21–2
data exclusivity 89
contract law 164–5, 169
good faith 176–7
international
CISG 160, 171
UNIDROIT Principles 160, 171–3, 174–6, 178
resource for treaty law 170–71
Convention on Biological Diversity (CBD) 15, 18, 77, 78
AUSFTA 148–50
conclusions 150–51
conflict between TRIPS and COP deliberations 135–43
expansion to TRIPS forum 143–6
inception of TRIPS and 132–4
introduction 131–2
objectives 132–3
TRIPS’ objective and principles 146–50
cooperative interpretation see competitive and cooperative interpretation
copyright 50, 51, 108
compulsory licences 109, 110–11
consumer viewpoint 68
exclusion from 104–5
harmonisation 34
United States 32, 40–41, 42–3
WCT 15, 35, 36, 91
Cornish, W. 41
Correa, C. 77, 81, 88, 103–4
Das, B-G. 143
data, test 109
exclusivity for 22, 88–9
Davies, L. 21
development balance of TRIPS basic premises 99
balancing interests 99–104
barriers to international trade 112–13
economic space dilemma 111–12
flexibilities and their effectiveness 108–11
institutional capability 111
participatory and compensatory regime for developing countries 107–12
political governance 113–16
scope of obligation 104–7
challenges of 122–4
conclusion 126
enforcement of IP rights 120–22
introduction 97–9
key outstanding issues 124–6
panels and Appellate Body 116–20
Diamond v Chakrabarty 75
digital technologies, protection of 91–3
DiMatteo, L. 169, 177
Dinwoodie, G. 107
Dispute Settlement Understanding (DSU) 55
Art 3.2 16, 47–8, 63–4
Art 3.5 12
Art 8 57, 61
Art 8.1 60
Art 13 13
Art 14 62
Art 17.6 14
Art 17.11 62
Art 23 24, 113–14
dispute settlement, WTO 54–5
Appellate Body 14, 54, 58, 60–61
independence 61–2
AUSFTA 24
cases 55–7, 59, 64, 105, 116–20, 171
Canada see under Canada
US see under United States
competitive and cooperative
interpretation 12–18
inter-governmental process outside 24
interpretations
difficulties 63–5
negotiated 12–13
Secretariat 63
‘soft’ law 65–6
moratorium 16
non-compliance with rulings 13
panels 14
establishment of 58–9
independence 61–2
selection of members 59–60, 61
precedent 59
procedures 57–8
receptive adjudication 13–16
trade sanctions 59
unilateral mechanism outside 113–14, 125–6
Doha Declaration 16–17, 64, 68, 81–2, 115–16, 123, 148
AUSFTA 21–2
balance of competing interests 103–4
compulsory licensing 16, 17, 82, 83, 84, 115, 116, 123
dominant position, abuse of see
forward-base regulatory model
Drahos, P. 7, 18, 24, 73, 134, 145
Dreyfuss, R. 50
drugs see pharmaceutical drugs
duress see forward-base regulatory
model
Dutfield, G. 18, 38
Ebke, W. 176
Ehlermann, C-D. 58, 61, 62, 64
Eli Lilly 73
equitable principles 16
Ericsson 39
Ethier, W. 65
European Patent Convention (EPC) 75
European Patent Office (EPO) 33, 61,
67, 88
European Union 32
barrier to international trade 112
bilateralism strategy 31, 36, 114
DSU, cases under 16, 55, 56
EC – Protection of Trademarks
and Geographic Indications
116–17, 118
evergreening, 21, 23
exclusions from patent protection
AUSFTA 21
pharmaceutical drugs 38
plants and animals 75–6
United States 20, 21
Farer, T. 168
Farmers’ Rights 77–8, 94
Feliciano, Fiorentino 62
Finnemore, M. 7
Fisher, M. 40
Food and Agriculture Organisation (FAO) 67, 77
Footer, M. 16
forum management/shopping 9, 24
United States 35, 36, 67
see also bilateral FTAs; regional
trade agreements
forward-base regulatory model
161–4
conclusion 180–81
contract law, borrowing from
170–71
contract law, international 171–6
good faith 176–8
introduction 159–61
present state of law 164–9
view from 178–80
France 38

*Australia v France* 176

fundamentalism, IP

costs/risks for developing countries 38

future 42–3

introduction 31–2

lessons of history 38–9

Japan and Asian tigers 39–40

United States 40–41

TRIPS in context 33–4

TRIPS and its alternatives 34–7

G-8 114

G-77 and China 135

game theory 162

Ganasan, A.V. 61

GATS (General Agreement on Trade in Services) 72

GATT (General Agreement on Tariffs and Trade) 54, 55, 99, 100, 125
generic drugs see pharmaceutical drugs

genes/gene sequencing 76

genetic resources, protection of 78–81, 126

see also Convention on Biological Diversity

geographical indications 16, 68, 108

Germany 38

*Certain German Interests in Polish Upper Silesia* 177

contracts and good faith 176–7

*Red Dove* case 75

Geuze, M. 47, 53, 59, 68

Ghanotakis, E. 16

Gibson, J. 18

Gillespie, A. 133

*Girard Trust Bank v Castle Apartments Inc* 177

Glassman, James 37

Goldstein, J. 55

Gowers, A. 37

Greenwald, J. 65

Grubb, M. 132, 134

Hague Agreement 105

Harris, D. 169

Helfer, L. 9, 18

Heller, M. 76

HIV/AIDS 66–7, 86

Hoekman, B. 51, 57, 58

Howse, R. 14

human rights 66, 78

Hurrell, A. 48

Hutchinson, D. 170–71

IBM 40

Idris, Kamil 37

India 22, 37, 38, 55, 57, 82

CBD 77

Farmers’ Rights 77

*India – Patents* 59

*India – Patents (US)* 64, 105, 116–17

indigenous and local communities see traditional knowledge

Indonesia 55

*Indonesia – Certain Measures Affecting Automobile Industry* 105, 117–18, 120

International Court of Justice 176

International Telecommunications Union (ITU) 67

International Union for the Protection of New Varieties of Plants (UPOV) 20, 76–8, 81

internet 91–3, 125

service providers (ISPs) 92

Ireland 38

Italy 38

Japan 19, 31, 38, 39–40, 114–15

*Japan – Tax on Alcoholic Beverages* 171

patent office 33, 88

Jennings, R. 175, 178

John, T. 24

Johnson, C. 39, 40

Juma, C. 98

Kaufmann, E. 165–6

Kelsen, H. 170

Keohane, R. 48, 54, 58–9

Khan, B. 41

Kim, L. 40

Krajewski, M. 16

Kuhlik, B. 20

Kuijper, P. 53

Lacarte, J. 61

Lang, R. 90
Laos 84
Latin America 11–12, 121
see also individual countries
Lawson, C. 7, 134, 149, 150
least-developed countries (LDCs) 52, 68, 82, 108, 124, 125
Doha Development Round 145, 148
Lempert, R. 162
Lennard, M. 14
Levis, M. 116
literalist approach 14, 119
lobbying by industry groups in US 73
McNair, A. 166, 170–71
McRae, D. 11
Madrid Agreement (Marks) 105
Mahoney, P. 162
Malanczuk, P. 170
marks 105
trade 89–91, 108
well-known 90
Maskus, K. 47, 54
Matthews, D. 17
Menell, P. 97
Merck 73
MFN (Most-Favoured Nation) basis 19, 51, 105, 117, 119, 149
Middle East 121
Moss, S. 162
multiagent models 162–3
multilateralism 66–7
conclusion 67–8
development of IPR protection 49–51
dispute settlement 48
Appellate Body, make-up of 60–61
cases 55–7
independence 61–2
interpretations 63–6
mechanism 54–5
panel, establishment of 58–9
panelists, selection of 59–60, 61
precedent 59
procedures 57–8
enforcement of TRIPS 51–2
introduction 46–9
substance of TRIPS 51
TRIPS Council 48, 52–4
Musungu, F. 34
Musungu, S. 110, 111, 116
Myanmar 84
NAFTA (North American Free Trade Agreement) 67, 74
Nahlik, S. 167
Nassar, N. 169
national treatment 105, 117, 119, 149
Nelson, J. 175
Netherlands 39
Obenski, S. 115
OECD (Organisation for Economic Co-operation and Development) 67, 108, 133, 134
Okediji, R. 98, 111
Oliva, M. 20
Oxley, A. 61
pacta sunt servanda 165, 177
Pakistan 55
Palmer, G. 134
Panjabi, R. 133
Paris Convention 15, 20, 50, 84, 85, 105, 143, 149
patents 50, 51, 147
AUSFTA 20–24, 149–50, 152
biotechnological inventions 75–6
compulsory licensing 110, 115, 116
Doha Declaration 16, 17, 82, 83, 84, 115, 116, 123
United States 20, 21–2, 83–4, 89
consumer viewpoint 68
exclusivity for test data 22, 88–9
harmonisation 33–4, 38, 87–8
joint inventorship 79
Patent Cooperation Treaty (PCT) 20, 87–8, 105, 108
Patent Law Treaty 20, 105
patent term restoration 86–7
pharmaceutical drugs 20, 22–4, 38, 56, 81–6, 115
plant varieties 76–8, 105
traditional knowledge 79
transitional arrangements 108
Pauwelyn, J. 10, 25
Penrose, E. 84
Petersmann, E-U. 61
Pfizer 73
pharmaceutical drugs 20, 38, 56, 81–3, 115
brands 90–91
exclusivity for test data 22, 88–9
institutional capability 111
manufacturing capacity 17, 110
US FTAs
Australia 20, 22–4
compulsory licensing 83–4
exclusivity for test data 22, 88–9
marks, well-known 90
parallel import, restraining 85–6
proposed with Thailand 84, 86
revocation of patents, prohibiting 85
Singapore 83–4, 86, 87, 89
trademarks 90
Vietnam 89
see also Doha Declaration
Philips 39
Picciotto, S. 14
plants 17–18, 20, 21, 105
patent protection for varieties 76–8, 105
Thailand 80
see also Convention on Biological Diversity
pluralism, legal 7–8
politics, world 48
precedent 59
Procter & Gamble 73
public health 47
Doha Declaration see Doha Declaration
Reagan, Ronald 41
rebus sic stantibus 175
Red Dove case 75
reform of treaty law see forward-base regulatory model
regional trade agreements (RTAs)
11–12, 35–6
Andean Community 19
Reichman, J. 51, 66
Reid, W. 79
Reiterer, M. 58
Rodriguez-Garavito, C. 12
Roffe, P. 73, 114
Roht-Arriaza, N. 78
Rome Convention 105
Ruiz, M. 19
Russia 121
Sands, P. 10
Schachter, O. 168
Schneiderman, D. 10
Sell, S. 16, 47, 50, 51, 56, 134, 143
Shaffer, G. 65, 67, 68
Shoyer, A. 60
Singapore
SUSFTA 73, 76, 77, 86, 87, 89
compulsory licences 83–4
digital technologies 91–2
revocation of patents 85
trademarks 90
Singham, S. 83
Slaughter, A. 8
Smith, P. 52
South Africa 115
Spain 38
Arbitral Award made by the King of Spain 178
stare decisis 59
Statman, M. 91
Steger, D. 62
Stevenson, G. 79
Sweden 38
Switzerland 38, 152
tariffs 72
technical assistance 108, 111–12
technological protection measures (TPMs) 91, 92, 125
technology transfers 47, 68, 76, 99, 107, 108
CBD’S COP deliberations 135, 136, 140, 141–2
Convention on Biological Diversity 134
key outstanding issue 125
US–Chile FTA 179–80
Temple of Preah Vihear 178
Templeman, S. 50
test data 109
exclusivity for 22, 88–9
Teubner, G. 25, 176
Texas Instruments 39
Textiles and Clothing, Agreement on 101
Thailand 17, 94
CBD 77
Farmers’ Rights 77
herbs and medicinal plants, protection of 80
plant variety protection law 77, 78
proposed TUSFTA 74, 76, 81, 84, 86, 92
traditional knowledge in medicinal field 79–80
Thomas, A. 168
Tilford, D. 133
time limits
implementation of TRIPS 52, 82
Trachtman, J. 9
trademarks 89–91, 108
Treaty 90, 105
traditional knowledge 17–18, 35, 78–9, 81, 126
Andean Community 19
CBD’S COP deliberations 137
Thailand 79–81
transitional arrangements 108
treaty law 164–9, 181
contract law as resource for 170–71
good faith 176, 177–8
Trilateral Cooperation Commission 21
TRIMS (Agreement on Trade-Related Investment Measures) 72
TRIPS Council 17, 48, 52–4, 82, 108, 121–2, 123, 124, 145, 151
TRIPS-plus terms see bilateral FTAs
United Kingdom 37
United Nations 98
Charter 165, 168, 180
Charter of Economic Rights and Duties of States 168, 180
Conference on Trade and Development (UNCTAD) 47, 48, 66, 67, 78
ICTSD and 99, 102, 108, 146
Development Program (UNDP) 67, 143
General Assembly 143, 151, 166–7
Havana Charter 99
High Commission on Human Rights 48, 66
International Law Commission 166, 167
Universal Declaration of Human Rights 168
United States 13, 16, 18, 37, 47, 50, 99
bilateral FTAs 18–20, 31, 36, 73–4, 114, 179
Australia 18–19, 20–24, 148–50, 152
Chile 179–80
data exclusivity 22, 88–9
digital agenda 91–3
life forms 76, 77, 81
marks, well-known 90
objectives 37, 74
patent term restoration 86–7
pharmaceuticals see under pharmaceutical drugs
plant varieties 77, 81
proposed with Thailand 74, 76, 81, 84, 86, 92
Singapore see under Singapore
single patent filing system 87
trademarks 90
traditional knowledge 81
Vietnam 86–7, 89, 92
biotechnological inventions
Diamond v Chakrabarty 75
Central America FTA 121
copyright laws 32, 40–41, 42–3, 107
Doha Declaration 17
DSU, cases under 16, 55, 56
US – Cuban Rum 13, 117
US – Gasoline 176
US – Homestyle Exemption 13, 15, 16, 106–7
US – Section 301 Trade Act 113–14
enforcement of IP rights 121
forum management 35, 36, 67
Japan 114–15
lobbying groups 73
non-compliance with rulings 13
patent office 33, 88
termination of international agreement 175
unilateral mechanism for IP protection 113–14